Solid lipid nanoparticles (SLNs) are an extremely versatile drug delivery system that could be the key to the future of medicine and the treatment of many diseases. This review focuses on the use of SLNs as the drug delivery vehicles that make better and more efficient therapy possible. SLNs offer several advantages, such as the ability to disperse hydrophobic drugs, ones which are poorly water soluble, drug stability, and controlled drug release, all of which result in low toxicity. Drugs delivered by SLNs have also shown a decrease in drug resistance in cancer cells. Apart from drug resistance in cancer therapy, the discussion also extends to the challenges and opportunities in the commercialization of SLNs, noting the significant market growth driven by their incorporation into high-profile products like COVID-19 vaccines. Besides the most important growth of the market, which is cannabis, the review also presents a look at the future and the technologies of SLNs, which can make individualized medicine possible through therapeutic approaches tuned specifically to the patient, including the possibility of the encapsulation of multiple drugs and personalized nanomedicine. Adding SLNs to the regular pharmaceutical use has the potential not only to elevate the healing performance and at the same time to manage the side effects of the drugs better but also to give a start to the new ways in treating complex diseases with accuracy and reduced side effects. As research work on SLNs goes on, these nanoparticles are going to be a very important factor in the new therapies that are coming and will offer a very strong platform for the management of diseases that is both very effective and targeted.
Sahu et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: